FDA Eases Testosterone Labels After 5,200-Man Trial, Narrowing Prostate Cancer Warning
Updated
Updated · Yahoo! Voices · Jul 29
FDA Eases Testosterone Labels After 5,200-Man Trial, Narrowing Prostate Cancer Warning
3 articles · Updated · Yahoo! Voices · Jul 29
Summary
June 2026 proposals would drop the label statement that testosterone therapy is unproven for age-related hypogonadism and limit a formal contraindication to men with metastatic prostate cancer.
A 5,200-man TRAVERSE trial drove the shift after finding no significant increase in heart attack or stroke risk, while FDA reviews also found no general prostate-cancer signal and no clear worsening of mild to moderate enlarged-prostate symptoms.
The rewrite follows February 2025 label changes that removed boxed cardiovascular warnings and added trial results, leaving elevated blood pressure as the main class-wide safety warning.
Over the next 12 to 24 months, the changes could widen prescribing for older men and give telehealth men's-health clinics more room to market TRT, while keeping pressure on doctors and patients to monitor labs, prostate status and blood pressure.